hmpl-a580
hmpl-a580: 1 clinical trial tracked.
hmpl-a580 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about hmpl-a580, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
Clinical Trial Registry Records (1)
A Phase I/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A580 in Participants With Advanced or Metastatic Solid Tumors
Primary endpoint: Maximum Tolerated Dose (MTD) and/or recommended dose(s) for expansion(RDE)
Interventionalopen186 targetStarted 2026-03Completion 2029-0114 sites · China, United StatesHutchmed